Scotia Capital Inc. Arbutus Biopharma Corp Transaction History

Scotia Capital Inc.

  • $16.1 Billion
  • Q1 2024

A detailed history of Scotia Capital Inc. transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Scotia Capital Inc. holds 29,040 shares of ABUS stock, worth $91,766. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,040
Previous 29,040 -0.0%
Holding current value
$91,766
Previous $72,000 2.78%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 03, 2023
SELL
$2.24 - $3.06 $336 - $459
-150 Reduced 0.51%
29,040 $66,000
Q1 2023

May 11, 2023
BUY
$2.23 - $3.1 $65,093 - $90,489
29,190 New
29,190 $88,000
Q3 2021

Nov 12, 2021
SELL
$2.65 - $4.62 $30,978 - $54,007
-11,690 Closed
0 $0
Q1 2021

May 06, 2021
SELL
$3.14 - $4.84 $442 - $682
-141 Reduced 1.19%
11,690 $39,000
Q4 2020

Feb 11, 2021
BUY
$2.76 - $4.97 $27 - $49
10 Added 0.08%
11,831 $42,000
Q3 2020

Nov 12, 2020
BUY
$1.75 - $6.2 $229 - $812
131 Added 1.12%
11,821 $37,000
Q1 2020

May 15, 2020
BUY
$1.01 - $3.42 $40 - $136
40 Added 0.34%
11,690 $12,000
Q4 2019

Feb 13, 2020
SELL
$0.87 - $2.89 $6,960 - $23,120
-8,000 Reduced 40.71%
11,650 $32,000
Q3 2019

Nov 14, 2019
SELL
$1.34 - $2.4 $4,020 - $7,200
-3,000 Reduced 13.25%
19,650 $30,000
Q2 2019

Aug 13, 2019
SELL
$1.46 - $4.44 $292 - $888
-200 Reduced 0.88%
22,650 $47,000
Q3 2018

Nov 14, 2018
SELL
$7.85 - $12.35 $48,670 - $76,570
-6,200 Reduced 21.34%
22,850 $216,000
Q4 2017

Feb 13, 2018
SELL
$4.45 - $7.7 $11,570 - $20,020
-2,600 Reduced 8.21%
29,050 $147,000
Q3 2017

Nov 14, 2017
BUY
$3.4 - $7.0 $34,510 - $71,050
10,150 Added 47.21%
31,650 $196,000
Q2 2017

Aug 15, 2017
BUY
N/A
21,500
21,500 $77,000

Others Institutions Holding ABUS

# of Institutions
130
Shares Held
82.2M
Call Options Held
4.82M
Put Options Held
546K
View Full List

About Arbutus Biopharma Corp

ABUS Quotes by TradingView
  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $474M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Scotia Capital Inc. Portfolio

Follow Scotia Capital Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Scotia Capital Inc., based on Form 13F filings with the SEC.

News

Stay updated on Scotia Capital Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email